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Background: Historically, liver surgeons have withheld venous thromboembolism (VTE) chemoprophy-
laxis due to perceived postoperative bleeding risk and theorized protective anticoagulation effects of a
hepatectomy. The relationships between extent of hepatectomy, postoperative VTE and bleeding events
were evaluated using the National Surgical Quality Improvement Program (NSQIP) database.
Methods: From 2005 to 2009, all elective open hepatectomies were identified. Factors associated with
30-day rates of VTE, postoperative transfusions and returns to the operating room (ROR), were analysed.
Results: The analysis included 5651 hepatectomies with 3376 (59.7%) partial, 585 (10.4%) left, 1134
(20.1%) right, and 556 (9.8%) extended. Complications included deep vein thrombosis (DVT) (1.93%),
pulmonary embolism (PE) (1.31%), venous thromboembolism (VTE) (2.88%), postoperative transfusion
(0.76%) and ROR with transfusion (0.44%). VTE increased with magnitude of hepatectomy (partial 2.13%,
left 2.05%, right 4.15%, extended 5.76%; P < 0.001) and outnumbered bleeding events (P < 0.001). Other
factors independently associated with VTE were aspartate aminotransferase (AST) 27 (P = 0.022),
American Society of Anesthesiologists (ASA) class 3 (P < 0.001), operative time >222 min (P = 0.043),
organ space infection (P < 0.001) and length of hospital stay 7 days (P = 0.004). VTE resulted in 30-day
mortality of 7.4% vs. 2.3% with no VTE (P = 0.001).
Conclusions: Contrary to the belief that transient postoperative liver insufficiency is protective, VTE
increases with extent of hepatectomy. VTE exceeds major bleeding events and is strongly associated with
mortality. These data support routine post-hepatectomy VTE chemoprophylaxis.
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Introduction
With regard to chemical venous thromboembolism (VTE) pro-
phylaxis, gastrointestinal surgeons have always needed to balance
the risk of peri-operative bleeding against the risk of VTE. For the
majority of these operations, peri-operative VTE chemoprophy-
laxis has proven effective and safe, and is now considered the
standard of care, especially in high-risk cancer patients.1–6 In spite
of this experience, liver surgeons have historically withheld peri-
operative VTE chemoprophylaxis mainly as a result of perceived
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peri-operative bleeding risk. Until the most recent decade of liver
surgery, in which hepatectomy mortality has dropped to 2.5%
nationally7 and 1% at top centres,8,9 liver resections were consid-
ered high-risk procedures10 with frequent peri-operative bleeding
events that impacted both short- and long-term outcomes.11
Further discouraging the utilization of VTE chemoprophylaxis,
liver surgeons have theorized that transient liver dysfunction after
a hepatectomy (related to inflow occlusion time, extent of hepa-
tectomy and liver remnant size) produced anticoagulation effects
that protected patients from thrombotic events. Using this logic,
the larger the magnitude of liver resection, the larger the bleeding
risk and the greater the likelihood of liver insufficiency, resulting
in a presumed lesser need for chemical VTE prophylaxis.
In addition to its associated high morbidity and mortality, post-
operative VTE is now also considered a preventable nosocomial
complication with both cost and reimbursement implications.5,12
In this current environment, defining the true relationships
between extent of hepatectomy, postoperative VTE and bleeding
events, could have a significant impact on practice patterns nation-
ally. Given the variability in clinical practice regarding this issue,
analysis of a large-scale multi-institutional dataset was required to
remove small dataset biases. The recent paradigm of using national
patient databases such as the American College of Surgeons
National Surgical Quality Improvement Program (ACS-NSQIP) to
study morbidity and mortality among general surgery operations
has allowed surgeons to transcend individual beliefs and customs,
looking beyond the bias of single-institution databases to study
issues on a broader, national level, which can more accurately
reflect general trends and behaviours in quality improvement.13
Using this paradigm, this project was designed to determine the
true relationships between extent of hepatectomy, clinically signifi-
cant bleeding risk and VTE risk.
The hypothesis of the present study was that, in current prac-
tice, the true postoperative VTE rate after a liver resection was
significantly greater than the rate of major postoperative bleeding
events. A secondary aim was to define the relationship between
extent of hepatectomy and VTE rates.
Methods
Data acquisition and patients
From the ACS-NSQIP participant use file (PUF) for 2005 to
2009, all hepatectomy procedures were identified. After exclud-
ing emergency cases and wedge resections [current procedural
terminology (CPT) code 47100] a total of 5651 hepatectomies
were included for analysis. The pre-operative NSQIP risk factors
assessed included age, gender, race, weight/body mass index,
albumin, haematocrit, platelets, blood urea nitrogen, creatinine,
partial thrombin time, international normalized ratio (INR),
alkaline phosphatase, aspartate aminotransferase (AST), biliru-
bin, American Society of Anesthesiologists (ASA) class, smoking,
chronic obstructive pulmonary disease, diabetes, bleeding disor-
der, ascites, pre-operative chemotherapy, pre-operative radiation
therapy, pre-operative transfusion and previous operation
within 30 days. Intra-operative factors included intra-operative
transfusion, operative time, concurrent operation and extent of
hepatectomy.
For thrombotic events within 30 days of a hepatectomy, the
analysis focused on three NSQIP postoperative occurrence vari-
ables: deep vein thrombosis (DVT), pulmonary embolism (PE) or
the combination of the two. For postoperative haemorrhagic
events, the analysis focused on two postoperative occurrence vari-
ables: postoperative transfusion within 72 h of surgery
and postoperative transfusion within 72 h of surgery with an
unplanned return to the operating room (ROR). Additional post-
operative complications included in the analysis were surgical site
infections, organ space infections (abscess/biloma), wound dis-
ruption (fascial dehiscence), length of stay and mortality.
The extent of hepatectomy was classified by the primary CPT
code and included the following liver resections by order of
increasing magnitude: partial (CPT 47120), left (47125), right
(47130), and extended (47122) hepatectomies. VTE was defined as
a clinically detected DVT or PE. Patients with both DVT and PE
documented were labelled only once for VTE. Major postopera-
tive bleeding was defined by the ACS-NSQIP variable ‘bleeding
transfusion,’ which included any postoperative transfusion
outside of the postoperative recovery room and excluding blood
finishing from the operating room. ROR was defined as a
re-operation within the same hospitalization. Patients were
labelled with simultaneous ROR and bleeding transfusion codes
with the complication of ‘ROR with transfusion,’ reflecting pre-
sumed major bleeding requiring operative intervention.
Statistical analysis
To identify clinical factors associated with VTE, postoperative
bleeding/transfusions and ROR with bleeding/transfusions,
univariate analyses were performed with chi-squared test or Fish-
er’s exact test for categorical data and Mann–Whitney U-test for
continuous data. Univariate factors with P < 0.15 were entered
into Cox proportional hazard models to find independent asso-
ciations with each major complication type. Statistical signifi-
cance was defined as a two-sided P < 0.05. Multivariate modelling
was reported with odds ratio (OR) and 95% confidence interval
(CI). All analyses were performed using IBM SPSS Version 19
software (IBM, Armonk, NY, USA).
Results
Patient characteristics and distribution of
hepatectomy types
From the cohort of 5651 patients, the median age was 60 years
(range, 17–89) with 48.7% male patients and 76.1% Caucasian
race. Regarding pre-operative risk factors, 66.0% were ASA class
3, with 16.7% smokers and 15.6% diabetics. Patients with
known bleeding disorders accounted for 3.4% of all study
patients. The case distribution included 3376 (59.7%) partial; 585
(10.4%) left; 1134 (20.1%) right; and 556 (9.8%) extended hepa-
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tectomies. Other clinically relevant pre-operative, intra-operative
and postoperative factors are described in Table 1.
Thrombotic and haemorrhagic event rates in relation
to extent of hepatectomy
Overall complication event rates included the following: DVT
(1.93%), PE (1.31%), VTE (2.88%), postoperative transfusion
(0.76%) and ROR with transfusion (0.44%). VTE event rates (2.1–
5.8%) were more frequent than postoperative transfusion rates
(0.6–1.3%) and/or ROR with transfusion rates (0.3–0.7%) across
all extents of hepatectomies (3.5–8.3 times, P < 0.001). Analysis of
the association between the magnitude of hepatectomy and VTE
rates showed a proportional relationship with VTE rates for
partial, left, right and extended hepatectomies, of 2.05%, 2.13%,
4.15%, and 5.76%, respectively (P < 0.001; Fig. 1). While intra-
operative transfusions 1 unit packed red blood cells (PRBC)
were relatively common (26.4%), massive intra-operative trans-
fusions (4 PRBC) were less common (9.0%) and postoperative
transfusions were rare (0.8%).
Factors associated with postoperative bleeding
requiring a transfusion
The rate of postoperative transfusion ranged from 0.6% for partial
hepatectomies up to 1.3% for extended hepatectomies, with a
0.8% overall rate. The univariate comparison of factors between
patients with and without major postoperative bleeding requiring
a transfusion and coded as ‘bleeding transfusion’ is detailed in
Table 2. Independent pre-operative factors associated with post-
operative transfusion included the following: bleeding disorder
[OR 16.95, 95% confidence interval (CI), 9.90–29.41, P < 0.001],
ASA class 3 (OR 2.13, 95% CI, 1.24–3.64, P = 0.006), albumin
<4 g/dl (OR 2.74, 95% CI, 1.33–5.65, P = 0.006), pre-operative
haematocrit <39% (OR 2.56, 95% CI, 1.33–4.93, P = 0.005) post-
operative deep organ space infection (OR 4.05, 95% CI, 2.36–6.94,
P < 0.001). In the multivariate model, the variable major vs. partial
hepatectomy trended towards statistical significance (P = 0.051).
Factors associated with return to operating room
with transfusion
The combined rate of ROR with transfusion ranged from 0.3%
after partial hepatectomies to 0.7% after right and extended hepa-
tectomies, with a 0.4% overall rate. The univariate analysis of
factors associated with patients with and without ROR with a
transfusion is detailed in Table 3. Using multivariate analysis,
independent pre-operative predictors of ROR with transfusion
included the following: bleeding disorder (OR 15.15, 95% CI,
8.47–27.03, P < 0.001), albumin <4 g/dl (OR 3.19, 95% CI, 1.19–
8.55, P = 0.021), pre-operative haematocrit < 39% (OR 2.99, 95%
CI, 1.28–6.99, P = 0.012) and major vs. partial hepatectomy (OR
2.92, 95% CI, 1.39–6.10, P = 0.005).
Factors associated with VTE
The univariate analysis of peri-operative risk factors associated
with postoperative VTE is detailed in Table 1. Using multivariate
analysis, the following peri-operative factors were independently
associated with VTE: major vs. partial hepatectomy (OR 2.58, CI,
1.93–3.47, P < 0.001), male gender (OR 2.92, 95% CI, 2.15–3.98, P
< 0.001), preoperative AST 27 IU/L (OR 1.41, 95% CI, 1.05–
1.89, P = 0.022), ASA class 3 (OR 1.90, 95% CI, 1.42–2.53, P <
0.001), operative time >222 min (OR 1.37, 95% CI, 1.01–1.86, P =
0.043), postoperative organ space infection (OR 10.64, 95% CI,
8.13–13.89, P < 0.001) and length of stay 7 days (OR 1.58, 95%
CI, 1.16–2.16, P = 0.004). Patients with VTE experienced a 30-day
mortality rate of 7.4% compared with 2.3% in non-VTE patients
(P = 0.001).
Discussion
The aim of the present study was to examine the true postop-
erative event rates of VTE, major bleeding requiring postopera-
tive transfusions, and ROR with transfusions. Based on clear
definitions and the presence of trained nurse reviewers for data
collection, the ACS-NSQIP database was ideally suited for this
purpose. This analysis showed that the VTE rate far exceeds the
event rate of postoperative bleeding complications requiring
transfusion, with or without return to the operating room. The
gradient between VTE event rate and bleeding complications
ranged from 3.5 to 8.3 times and increased significantly with the
magnitude of hepatectomy.
Published hepatectomy bleeding event rates range from 1% to
8%,14 with most series focusing their data on intra-operative
bleeding and transfusion rates. By focusing this analysis on defin-
ing the true rates of major postoperative bleeding events for each
extent of hepatectomy in a large, objective dataset, the relative
incidence of VTE and bleeding events were determined. This
analysis indicates that VTE is far more common than previously
recognized and that the rate of clinically significant post-
operative bleeding has probably decreased over the last decade,
which is reflected in the improved postoperative mortality rate
for hepatectomies.7,9
Accurate determination of these event rates is critical to the
discussion of peri-operative VTE prophylaxis in liver surgery. Pre-
vious studies on surgical VTE prophylaxis have included guide-
lines for general abdominal surgery without defining specific
strategies for liver resections.4,15 This lack of specificity has made it
difficult to extrapolate results to liver resections, which are known
to have higher bleeding and transfusion rates than most general
surgery operations.13 Within this data vacuum, some surgeons
have criticized these general surgery consensus recommen-
dations for peri-operative and postoperative VTE chemopro-
phylaxis with unfractionated heparin or low-molecular-weight
heparin.1,16,17
The second focus of this analysis was a determination of the
relationship between the magnitude of hepatectomy and the post-
operative VTE rate. In this portion of the analysis, the traditional
concept that auto-anticoagulation from physiologic postoperative
liver dysfunction protects post-hepatectomy patients from VTE
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Table 1 Factors associated with no VTE vs. VTE
Clinical characteristic All patients (n = 5651) No VTE (DVT or PTE) VTE (DVT or PTE) P
n or median % n or median % n or median %
n 5651 100% 5488 163
Pre-operative factors
Median age (range), years 60 60 62 0.040
Gender, male 2752 48.7% 2648 48.3% 104 63.8% <0.001
Race, white 4299 76.1% 4161 75.8% 138 84.7% 0.009
Weight, kg 77.7 77.7 81.7 0.059
BMI 27 27 27.2 0.696
Albumin 4 2874 50.9% 2804 51.1% 70 42.9% 0.047
Alkaline phosphatise 93 93 105 0.004
AST 27 27 31 0.002
ASA class 3 3728 66.0% 3604 65.7% 124 76.1% 0.006
Ascites 72 1.3% 67 1.2% 5 3.1% 0.056
Peri-operative
Operative time, min 222 220 297 <0.001
Operative time >222 min 2825 50.0% 2698 49.2% 127 77.9% <0.001
Any intra-operative transfusion 1492 26.4% 1413 25.7% 79 48.5% <0.001
RBC 4 510 9.0% 477 8.7% 33 20.2% <0.001
Concurrent Operation 223 3.9% 211 3.8% 12 7.4% 0.037
Extent of hepatectomy <0.001
Partial 3376 59.7% 3304 60.2% 72 44.2%
Left 585 10.4% 573 10.4% 12 7.4%
Right 1134 20.1% 1087 19.8% 47 28.8%
Extended 556 9.8% 524 9.5% 32 19.6%
Partial vs. left/right/extended 3376 59.7% 3304 60.2% 72 44.2% <0.001
Right/extended vs. left/partial <0.001
Right/Extended 1690 29.9% 1611 29.4% 79 48.5%
Left/Partial 3961 70.1% 3877 70.6% 84 51.5%
Postoperative transfusion 43 0.8% 38 0.7% 5 3.1% 0.007
Return to operating room (ROR) 256 4.5% 222 4.0% 34 20.9% <0.001
ROR with postoperative transfusion 25 0.4% 22 0.4% 3 1.8% 0.034
SSSI 271 4.8% 257 4.7% 14 8.6% 0.037
DSSI 54 1.0% 49 0.9% 5 3.1% 0.019
Organ space infection 363 6.4% 323 5.9% 40 24.5% <0.001
Fascial dehiscence 49 0.9% 41 0.7% 8 4.9% 0.001
Postoperative LOS 6 6 11 <0.001
Postoperative LOS 7 2395 42.4% 2260 41.2% 135 82.8% <0.001
Death within 30 days 137 2.4% 125 2.3% 12 7.4% 0.001
BMI, body mass index; AST, aspartate aminotransferase; ASA, American Society of Anesthesiologists; RBC, (units) red blood cells; ROR, return to
the operating room; SSSI, superficial surgical site infection; DSSI, deep surgical site infection; LOS, length of stay.
Not significant: white blood cells, platelets, blood urea nitrogen, creatinine, haematocrit, international normalized ratio, partial thrombin time, total
bilirubin, alcohol use, pulmonary disease, smoking, diabetes, pre-operative radiation therapy, pre-operative transfusion, bleeding disorder, operation
in preceding 30 days, high level resident involvement; pre-operative chemotherapy within 30 days; pre-operative weight loss 10%.
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was tested. Contrary to that perception, the VTE rate actually
increased in proportion to extent of hepatectomy, disproving this
long-held belief. These data suggest that patients undergoing
larger volume resections, which were traditionally thought to be
the most protected by auto-anticoagulation, are actually the most
at risk for VTE. This relationship could be as a result of anatomic
factors (caval manipulation), biological factors (greater tumour
burden and/or post-hepatectomy prothrombotic state18) and/
or clinical factors (decreased compliance with the use of
postoperative VTE chemoprophylaxis) with larger volume resec-
tions. The clinical importance of VTE was manifested in its
strong association with higher rates of prolonged length of stay
and death within 30 days in this cohort.
The relatively low rate of major postoperative bleeding events
combined with the proportional association between magnitude
of hepatectomy and postoperative VTE make a very strong argu-
ment for the use of VTE chemoprophylaxis in all hepatectomy
patients, regardless of magnitude of resection. The only exception
to this recommendation would be patients with pre-operatively
known bleeding disorders (including bleeding diatheses), as
this group was disproportionately at risk for postoperative
bleeding events in the present analysis. For these patients, confir-
mation of haemostasis would be advised prior to initiating VTE
chemoprophylaxis.
One other interesting observation from this analysis is that the
development of a postoperative organ space infection, which is
likely a biloma in this population, was most strongly associated
with postoperative VTE with an OR of 10.64. This covariate rela-
tionship between postoperative fluid collection, VTE and other
major adverse outcomes is well explained by the frequent disabil-
ity incurred by postoperative bilomas, including activation of
inflammatory cascades, additional drainage procedures, infection,
immobility and longer lengths of stay. This observation suggests
that, in addition to routine use of VTE chemoprophylaxis, hyper-
vigilance during the operation regarding control of biliary struc-
tures may be the most important indirect measure for VTE
prevention.
The two questions examined in this study have direct bearing
on unique areas of VTE chemoprophylaxis. The immediate post-
operative bleeding event rate is relevant to the question of whether
liver surgery patients should be given pre-operative VTE chemo-
prophylaxis, as well as the drug and dose choices in the immediate
postoperative period. In contrast, the data regarding elevated VTE
rates for patients with large volume liver resection has more
impact on VTE chemoprophylaxis practice during the middle and
later portions of the hospitalization, when the INR would be
expected to have peaked and recovered.
The major potential limitation of the present study is a lack of
complete data regarding the utilization of VTE prophylaxis in this
population.19,20 Given the general fear of bleeding events, it is
reasonable to assume that a larger proportion of minor hepatec-
tomy NSQIP patients received VTE chemoprophylaxis in the
immediate postoperative period, compared with patients treated
with major hepatectomies. However, the exact magnitude of this
difference is unknown. If this assumption is at least in part correct,
then the results of the present study, which indicate that major
hepatectomy patients are the most likely to benefit from VTE
chemoprophylaxis, have the opportunity to significantly improve
outcomes through a seminal change in practice. Unfortunately,
without the specific data on drug choice, dosing and timing, no
comments on the risks or benefits of either pre-operative dosing
(in the operating room before incision) or post-discharge dosing
could be made.16,17 These two areas remain open to further clari-
fication and study.
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Figure 1 National rates of venous thromboembolism (VTE) vs. bleeding transfusion vs. return to the operating room with bleeding transfu-
sion. VTE rates far exceed rates of bleeding complications
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Table 2 Factors associated with postoperative bleeding and transfusion
Clinical characteristic All patients (n = 5651) No postoperative tranfusion Postoperative transfusion P
n or median % n or median % n or median %
n 5651 100% 5608 43
Pre-operative factors
Median age (range), years 60 60 59 0.964
Gender, male 2752 48.7% 2730 48.7% 22 51.2% 0.762
Race, white 4299 76.1% 4264 76.0% 35 81.4% 0.477
Weight, kg 77.7 77.7 78.2 0.949
Albumin 4 g/dl 2874 50.9% 2863 51.1% 11 25.6% 0.001
Haematocrit 39% 2983 52.8% 2970 53.0% 13 30.2% 0.003
PTT 29 s 1963 34.7% 1940 34.6% 23 53.5% 0.015
Alkaline phosphatase 93 93 151 <0.001
AST 27 27 46.5 <0.001
ASA class 3 3728 66.0% 3691 65.8% 37 86.0% 0.005
Ascites 72 1.3% 71 1.3% 1 2.3% 0.425
Bleeding disorder 191 3.4% 186 3.3% 5 11.6% 0.014
Peri-operative
Operative time, min 222 222 350 <0.001
Operative time >222 min 2825 50.0% 2790 49.8% 35 81.4% <0.001
Any intra-operative transfusion 1492 26.4% 1466 26.1% 26 60.5% <0.001
RBC 4 510 9.0% 488 8.7% 22 51.2% <0.001
Concurrent operation 223 3.9% 218 3.9% 5 11.6% 0.026
Extent of hepatectomy 0.198
Partial 3376 59.7% 3355 59.8% 21 48.8%
Left 585 10.4% 582 10.4% 3 7.0%
Right 1134 20.1% 1122 20.0% 12 27.9%
Extended 556 9.8% 549 9.8% 7 16.3%
Partial vs. left/right/extended 3376 59.7% 3355 59.8% 21 48.8% 0.161
Right/extended vs. left/partial 0.045
Right/extended 1690 29.9% 1671 29.8% 19 44.2%
Left/partial 3961 70.1% 3937 70.2% 24 55.8%
DVT 109 30.4% 105 30.4% 4 9.3% 0.009
PE 74 29.9% 72 29.8% 2 4.7% 0.108
VTE 163 69.6% 158 69.6% 5 11.6% 0.007
Return to OR 256 4.5% 231 4.1% 25 58.1% <0.001
Organ Space Infection 363 6.4% 355 6.3% 8 18.6% 0.005
Postoperative LOS 6 6 13 <0.001
Postoperative LOS 7 2395 42.4% 2361 42.1% 34 79.1% <0.001
Death within 30 days 137 2.4% 130 2.3% 7 16.3% <0.001
PTT, partial thrombin time; AST aspartate aminotransferase; ASA, American Society of Anesthesiologists; RBC, (units) red blood cells; DVT, deep vein
thrombosis; PE, pulmonary embolus; VTE, venous thromboembolism; OR, operating room; LOS, length of stay.
Not significant: white blood cells, platelets, blood urea nitrogen, creatinine, total bilirubin, alcohol use, pulmonary disease, smoking, diabetes,
preoperative radiation therapy, preoperative transfusion, operation in preceding 30 days, high level resident involvement, surgical site infection, fascial
dehiscence, preoperative chemotherapy within 30 days; preoperative weight loss 10%, body mass index, international normalized ratio.
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Table 3 Factors associated with return to operating room (ROR) with postoperative bleeding and transfusion
Clinical characteristic All patients (n = 5651) No ROR with transfusion ROR with transfusion P
n or median % n or median % n or median %
n 5651 5626 25
Pre-operative factors
Median age (range), years 60 60 59 0.943
Gender, male 2752 48.7% 2737 48.6% 15 60.0% 0.176
Race, white 4299 76.1% 4278 76.0% 21 84.0% 0.482
Weight, kg 77.7 77.7 74.1 0.140
BMI 27 27 25.1 0.103
Albumin 4 g/dl 2874 50.9% 2869 51.0% 5 20.0% 0.002
Median haematocrit 39.3 39.3 34.5 <0.001
Haematocrit 39% 2983 52.8% 2976 52.9% 7 28.0% 0.015
Median BUN 14 14 17.5 0.101
PTT 29 s 1963 34.7% 1950 34.7% 13 52.0% 0.090
Alkaline phosphatase 93 93 148.5 <0.001
AST 27 27 55 <0.001
ASA class 3 3728 66.0% 3706 65.9% 22 88.0% 0.019
Ascites 72 1.3% 71 1.3% 1 4.0% 0.275
Bleeding disorder 191 3.4% 187 3.3% 4 16.0% 0.009
Peri-operative
Operative time, min 222 222 332 <0.001
Operative time >222 min 2825 50.0% 2805 49.9% 20 80.0% 0.002
Any intra-operative transfusion 1492 26.4% 1477 26.3% 15 60.0% <0.001
RBC 4 510 9.0% 498 8.9% 12 48.0% <0.001
Concurrent Operation 223 3.9% 221 3.9% 2 8.0% 0.259
Extent of hepatectomy 0.139
Partial 3376 59.7% 3366 59.8% 10 40.0%
Left 585 10.4% 582 10.3% 3 12.0%
Right 1134 20.1% 1126 20.0% 8 32.0%
Extended 556 9.8% 552 9.8% 4 16.0%
Partial vs. left/right/extended 3376 59.7% 3366 59.8% 10 40.0% 0.064
Right/extended vs. left/partial 0.077
Right/extended 1690 29.9% 1678 29.8% 12 48.0%
Left/partial 3961 70.1% 3948 70.2% 13 52.0%
DVT 109 30.4% 106 1.9% 3 12.0% 0.012
PE 74 29.9% 73 1.3% 1 4.0% 0.281
VTE 163 69.6% 160 2.8% 3 12.0% 0.034
Organ Space Infection 363 6.4% 359 6.4% 4 16.0% 0.073
Postoperative LOS 6 6 17 <0.001
Postoperative LOS 7 2395 42.4% 2373 42.2% 22 88.0% <0.001
Death within 30 days 137 2.4% 133 2.4% 4 16.0% 0.003
BMI, body mass index; BUN, blood urea nitrogen; PTT, partial thrombin time; AST aspartate aminotransferase; ASA, American Society of Anesthe-
siologists; RBC (units) red blood cells; DVT, deep vein thrombosis; PE, pulmonary embolus; VTE, venous thromboembolism; LOS, length of stay.
Not significant: white blood cells, platelets, creatinine, alcohol use, total bilirubin, pulmonary disease, smoking, diabetes, pre-operative radiation
therapy, pre-operative transfusion, operation in preceding 30 days, high level resident involvement, surgical site infection; fascial dehiscence;
pre-operative chemotherapy within 30 days, international normalized ratio; weight loss  10%.
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Conclusions
In contrast to the common belief among liver surgeons that tran-
sient postoperative liver insufficiency and auto-anticoagulation
protects against postoperative VTE, this analysis confirms that
VTE risk actually increases with extent of resection. Post-
operative VTE incidence far exceeds major bleeding events among
all extents of hepatectomy and is highly associated with post-
operative mortality. With the exception of patients with bleeding
disorders and those with overt ongoing bleeding, these results
support a recommendation for routine postoperative VTE
chemoprophylaxis in post-hepatectomy patients, including those
undergoing major resections requiring longer operative times.
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